A Study of CM336 in Patients With Relapsed or Refractory Autoimmune Cytopenia
Key facts
- Phase
- Phase 1/2
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Keymed Biosciences Co.Ltd
- Trial code
- NCT07175493
- Record updated
- 17 December 2025
- Original description
To evaluate the efficacy and safety of CM336 (BCMA/CD3 Bispecific Antibody) in the treatment of patients with relapsed or refractory autoimmune cytopeniaRead full original descriptionShow less
A Phase 1/2 Clinical Study of CM336 Injection in Patients With Relapsed or Refractory Autoimmune Cytopenia
To evaluate the efficacy and safety of CM336 (BCMA/CD3 Bispecific Antibody) in the treatment of patients with relapsed or refractory autoimmune cytopenia
Inclusion: Voluntary provision of written informed consent and ability to comply with protocol requirements; Age ≥18 years, male or female; Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2; Confirmed diagnosis of immune thrombocytopenia (ITP), warm autoimmune hemolytic anemia (wAIHA), cold agglutinin disease (CAD), mixed autoimmune hemolytic anemia (mAIHA) or Evans Syndrome; Relapsed or refractory autoimmune hemolytic anemia.
Exclusion: Received any treatment of anti-B Cell Maturation Antigen(BCMA) antibody; Secondary ITP or AIHA caused by any reason. Subjects with positive autoimmune antibodies but without a clear diagnosis of any other autoimmune diseases are allowed to be enrolled; History of critical diseases that, in the opinion of the investigator, may pose a risk to the safety of subjects or whose exacerbation during the study could compromise the efficacy or safety analysis of the results; Other types of AIHA or other types of cytopenia; Evaluated unsuitable to participant in this study by investigator.